While Supernus Pharmaceuticals Inc has overperformed by 3.15%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SUPN rose by 36.92%, with highs and lows ranging from $49.66 to $29.16, whereas the simple moving average jumped by 35.98% in the last 200 days.
On October 09, 2025, Piper Sandler Upgraded Supernus Pharmaceuticals Inc (NASDAQ: SUPN) to Overweight. A report published by Cantor Fitzgerald on July 30, 2025, Upgraded its rating to ‘Overweight’ for SUPN. Cantor Fitzgerald also Downgraded SUPN shares as ‘Neutral’, setting a target price of $36 on the company’s shares in a report dated February 19, 2025. Cantor Fitzgerald Initiated an Overweight rating on January 06, 2025, and assigned a price target of $57. Piper Sandler September 11, 2024d its ‘Overweight’ rating to ‘Neutral’ for SUPN, as published in its report on September 11, 2024. Jefferies’s report from January 03, 2023 suggests a price prediction of $45 for SUPN shares, giving the stock a ‘Buy’ rating. Jefferies also rated the stock as ‘Buy’.
Analysis of Supernus Pharmaceuticals Inc (SUPN)
Further, the quarter-over-quarter decrease in sales is -1.71%, showing a negative trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Supernus Pharmaceuticals Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of 6.38% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.43, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and SUPN is recording an average volume of 804.65K. On a monthly basis, the volatility of the stock is set at 2.76%, whereas on a weekly basis, it is put at 3.11%, with a gain of 3.23% over the past seven days. Furthermore, long-term investors anticipate a median target price of $54.20, showing growth from the present price of $49.51, which can serve as yet another indication of whether SUPN is worth investing in or should be passed over.
How Do You Analyze Supernus Pharmaceuticals Inc Shares?
Supernus Pharmaceuticals Inc (SUPN) is based in the USA and is one of the most prominent companies operating in the Drug Manufacturers – Specialty & Generic market. When comparing Supernus Pharmaceuticals Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 43.27, there is a growth in quarterly earnings of 11.14%.
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 5.79%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 106.14% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
